SARS-CoV-2 and Influenza: A Comparative Overview and Treatment Implications

Laura D. Manzanares-Meza and Oscar Medina-Contreras

TX_1:ABS~AT/TX_2:ABS~AT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Alphainfluenzavirus are RNA viruses that cause coronavirus disease-19 and influenza, respectively. Both viruses infect the respiratory tract, show similar symptoms, and use surface proteins to infect the host. Influenza requires hemagglutinin and neuraminidase to infect, whereas SARS-CoV-2 uses protein S. Both viruses depend on a viral RNA polymerase to express their proteins, but only SARS-CoV-2 has a proofreading mechanism, which results in a low mutation rate compared to influenza. E1KC4 and camostat mesylate are potential inhibitors of SARS- CoV-2 S protein, achieving an effect similar to oseltamivir. Due to the SARS-CoV-2 low mutation rate, nucleoside analogs have been developed (such as EIDD-2801), which insert lethal mutations in the viral RNA. Furthermore, the SARS-CoV-2 low mutation rate suggests that a vaccine, as well as the immunity developed in recovered patients, could provide long-lasting protection compared to vaccines against influenza, which are rendered obsolete as the virus mutates.

Latest articles

Euzebiusz Jamrozik The global response to the recent coronavirus pandemic has revealed...
Abdulrahman Koshak et al. Effective treatment for patients with the novel Coronavirus...
James A. Thorp et al. Objectives: Assess rates of adverse events (AE)...
VaxJustice.org The rates of death and injury from Covid-19 never justi ed...
Vernon Coleman When the first practical polio vaccine was made in the...
Mike Campbell The study involved about 200 hungry mosquitos biting a human...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Thank you!

The form has been submitted successfully!